Superworth

AbCellera Biologics EV/EBIT ABCL

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2022.

Today, Oct 23, 2026
n/m
an operating loss
Last meaningful
5.1×
Apr 2023
Peer median
16.4×

AbCellera Biologics has no meaningful EV/EBIT today: it made an operating loss of $225.2M over the last twelve months.

It was last meaningful in Apr 2023, at 5.1×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
20235.1×5.1×7.2×
20226.3×4.8×10.8×

Against its peers

Companies in Drug Manufacturers - General nearest AbCellera Biologics' size, closest first, today.

CompanyEV/EBIT
ABCLAbCellera Biologicsn/m
OGNOrganon9.5×
LQDALiquidia21.7×
ARQTArcutis Biotherapeutics111×
INDVIndivior Pharmaceuticals7.8×
NRIXNurix Therapeutics7.1×
PBHPrestige Consumer Healthcare14.5×
KNSAKiniksa Pharmaceuticals International54.6×
LGNDLigand Pharmaceuticals57.7×
HRMYHarmony Biosciences6.9×
AMRXAmneal Pharmaceuticals18.3×
Peer median16.4×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on AbCellera Biologics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.